Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX® (moxifloxacin HCl) for a new use ...

Dec. 19, 2005 —Australia's Therapeutic Goods Administration has approved anecortave acetate 15-mg suspension for depot injection in the treatment of subfoveal choroidal neovascularization due to ...

Oct. 13, 2004 -- The U.S. Food and Drug Administration (FDA) approved in July revisions to safety labeling to advise healthcare professionals of the following changes: tenofovir disoproxil fumarate ...

SAN FRANCISCO, Sept. 29, 2006 – The efficacy of monotherapy with the once-daily, broad-spectrum antibiotic AVELOX® (moxifloxacin HCl) in the treatment of complicated intra-abdominal infections (cIAI) ...

Dr Reddy's Laboratories said that after a nod from United States Food & Drug Administration (USFDA) it has launched Moxifloxacin Hydrochloride Tablets 400 mg in the US. In the US, Moxifloxacin will be ...

Dr Reddy’s Laboratories Ltd announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox (moxifloxacin HCl) tablets 400mg in the ...

The new research report prepared by Market.us Research is titled ” Moxifloxacin HCl Analysis with Future Scope, Current Market Scenario, and Forecast to 2029. ” The business intelligence report from ...

It is a fluoroquinolone antibacterial indicated for treating infections in adults Lupin’s US subsidiary, Gavis Pharmaceuticals has received tentative approval for its Moxifloxacin Hydrochloride ...

Moxifloxacin hydrochloride is a crystalline powder which is soluble in DMSO (dimethyl sulfoxide) and dimethyl formamide. Moxifloxacin hydrochloride is an 8-methoxy-fluoroquinone compound with ...

Dr Reddy's Laboratories Ltd has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of a wide range of diseases, including pneumonia, bronchitis and skin infections.The drug ...

Global pharma major Dr. Reddy’s Laboratories Limited has informed BSE today that it has launched Moxifloxacin Hydrochloride tablets in the US market on March 4, 2014 following approval from US Food ...